Showing 361 - 370 of 1,415
Persistent link: https://www.econbiz.de/10005449213
Background: Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron concentrations and serum ferritin levels to a similar extent as infusional deferoxamine. Objective: To determine the cost effectiveness of deferasirox versus deferoxamine in...
Persistent link: https://www.econbiz.de/10005449228
Background: The PCI-CURE (Percutaneous Coronary Intervention-Clopidogrel in Unstable Angina to Prevent Recurrent Events) and CREDO (Clopidogrel for the Reduction of Events During Observation) studies have demonstrated that, in addition to aspirin, pre-treatment with clopidogrel followed by...
Persistent link: https://www.econbiz.de/10005449235
The objective of this review was to analyse the methods of paediatric and adult cost-utility analyses (CUAs) conducted in US populations, and to compare the cost-utility ratios of health interventions by classifying them by disease prevention stage, intervention category and primary disease...
Persistent link: https://www.econbiz.de/10005449259
Objective: To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of...
Persistent link: https://www.econbiz.de/10005449271
Background: Migraine is a common, chronic, neurovascular disorder, generally characterised by attacks of severe headache and autonomic nervous system dysfunction. Triptans are selective serotonin 5-HT1B/1D receptor agonists that represent effective therapeutic options for moderate-to-severe...
Persistent link: https://www.econbiz.de/10005449274
Background: Anticoagulation therapy with warfarin is widely considered the standard of care for stoke prophylaxis in patients with atrial fibrillation who are at high risk of stroke. Community-based studies in the US have reported that the effectiveness of anticoagulation varies by management...
Persistent link: https://www.econbiz.de/10005449282
Background: In Sweden, risperidone long-acting injectable (RLAI) is generally used in a population of schizophrenia patients who are at a high risk of being non-compliant. However, RLAI might also be suitable for use in the general schizophrenia population. Objectives: To analyse the clinical...
Persistent link: https://www.econbiz.de/10008506287
Persistent link: https://www.econbiz.de/10005167134
DOI: 10.2165/0019053-200826100-00001
Persistent link: https://www.econbiz.de/10005243081